Oct 16th – 19th 2022, Nashville, TN
Visit us at booth 1719 to learn about our genomic diagnostic tests for interstitial lung disease and lung cancer.
Join our industry event: Oct 18th, 1:45-2:30pm CT
Improving ILD Diagnosis and Predicting Clinical Progression with the Envisia Genomic Classifier
Join our industry event: Oct 18th, 1:45-2:30pm CT
Improving ILD Diagnosis and Predicting Clinical Progression with the Envisia Genomic Classifier
ATS Webinar
Presented by: Fayez Kheir, MD & Mary Beth Scholand, MD.
In this webinar speakers review published data on the Envisia Genomic Classifier, updates from the recent IPF/PPF clinical guideline, and how they have integrated the classifier into their practice.
In this webinar speakers review published data on the Envisia Genomic Classifier, updates from the recent IPF/PPF clinical guideline, and how they have integrated the classifier into their practice.
Envisia detects genomic UIP pattern to improve ILD diagnostic and prognostic confidence.
Percepta GSC stratifies the risk of lung cancer to guide patient management for when bronchoscopy is inconclusive.
PIPELINE
Percepta Nasal Swab brings genomic objectivity to lung nodule risk assessment with a simple, non-invasive tool.
Transform uncertainty into confidence
Veracyte offers a suite of actionable genomic tests that can offer greater confidence and clarity at every step of your lung cancer and interstitial lung disease patient management.